What is the market's earnings forecast for Maxcyte next quarter?

What factors drove the changes in Maxcyte's revenue and profit?

What is Maxcyte's gross profit margin?

What guidance did Maxcyte's management provide for the next earnings period?

What were the key takeaways from Maxcyte’s earnings call?

Did Maxcyte beat or miss consensus estimates last quarter?

What does Maxcyte do and what are its main business segments?

What were the key takeaways from Maxcyte's earnings call?

- **Revenue Guidance Downgrade**: 2025 core revenue revised to flat to -10% ($29.5M-$32.5M) due to customer inventory management and program consolidation, with $5M reduction from prior guidance.
- **Instrument Sales Growth**: +22% YoY in instruments, driven by lower-priced systems and global expansion, despite broader capital equipment hesitancy.
- **SPL Pipeline Strength**: 3 new SPL signings in 2025, 14 SPL customers with active clinical programs, and 5 programs expected to enter pivotal studies in 2026-2028.
- **SeQure Dx Integration**: On track for $2M+ annual revenue, with services now fully integrated into MaxCyte's platform.
- **Customer Reorganization Impact**: Short-term PA and license revenue decline from largest customer, but no impact on long-term licensing agreements.


**【CEO Summary Section】**
- **Revenue Guidance Update**: Core business revenue for 2025 revised to flat to -10% ($29.5M-$32.5M), down from previous 8%-15% growth guidance. Reduction driven by $1.5M in PA revenue decline (inventory management at a large customer) and $2M in license revenue decline (customer program consolidation and manufacturing reorganization). Instrument revenue growth (+22% YoY) partially offset the decline.
- **Strategic Platform Licenses (SPLs)**: Signed 3 new SPLs in 2025 (Adicet Bio, Anocca AB, and 1 undisclosed), bringing total to 31. 14 SPL customers have active clinical programs, with 5 expected to enter pivotal studies in 2026-2028.
- **Long-Term Outlook**: Expect return to growth in 2026, driven by Asia Pacific expansion, new platform launches, and SPL pipeline diversification across blood cancer, solid tumors, and genetic diseases.
- **SeQure Dx Integration**: On track to meet $2M+ annual revenue target. Services now integrated into MaxCyte, with 3 assays supporting gene editing risk assessment for ex vivo and in vivo therapies.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Total revenue $8.5M (down 18% YoY), with core revenue $8.2M (+8% YoY). Instrument revenue $2.1M (+22% YoY), PA revenue $3.1M (+3% YoY), license revenue flat at $2.6M.
- **Gross Margin**: 82% (non-GAAP adjusted 83%), down from 86% YoY due to inventory provisions.
- **Operating Expenses**: $21.2M (flat YoY), with modest OpEx reduction despite SeQure Dx integration costs.
- **Cash Position**: $165.2M in cash, equivalents, and investments, expected to decline to $155M by year-end due to lower revenue.
- **SPL Program Revenue**: $0.3M in Q2 (CASGEVY royalties), with $5M+ expected for 2025.

**【Q&A Highlights】**
- **Customer Reorganization Impact**: Largest customer's manufacturing consolidation caused short-term PA and license revenue decline, but no impact on long-term licensing agreements. Customer expects to resume purchases post-reorganization.
- **Instrument Sales Momentum**: 22% YoY growth in instruments driven by lower-priced systems and global expansion (e.g., Asia Pacific). Management expects continued growth despite macroeconomic headwinds.
- **2025 Revenue Cadence**: Slight Q4 weighting in core revenue, with variability tied to customer program execution.
- **SPL Pipeline Resilience**: Despite 4 program closures, 4 new programs entered the clinic, maintaining 18 active clinical programs. New SPL signings (3-5/year) offset program attrition.


MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

- **Q1 Revenue Resilience**: $10.4M total revenue, with PA growth offsetting instrument cautiousness.
- **SeQure Dx Breakthrough**: $2M+ annual revenue target on track, expanding into in-vivo safety assessments.
- **SPL Momentum**: 29 active agreements, CASGEVY adoption accelerating with 90+ patients treated.
- **Financial Strength**: $174.7M cash, 8-15% core growth guidance reaffirmed with $5M SPL revenue.
- **Strategic Expansion**: New products in 2025, LMP/AAV partnerships to complement electroporation.

**【CEO Business Overview】**
- Q1 2025 total revenue: $10.4 million, including core revenue of $8.2 million and SPL program revenue of $2.1 million.
- Instrument installed base grows to 787 units, with PA revenue up 13% YoY driven by clinical and early-stage customers.
- SeQure Dx integration on track for $2 million+ annual revenue, with strong customer interest in gene editing safety assessments.
- 29 active SPL agreements, reaffirming 2025 guidance amid cautious customer capital spending.
- CASGEVY momentum: Vertex reports 90+ patients completing cell collection, with >180 referred to treatment centers.

**【CFO Financial Highlights】**
- Core revenue stable QoQ at $8.2 million, with PA revenue growth (3.9M vs 3.4M YoY) offsetting instrument revenue decline (1.4M vs 1.9M YoY).
- Gross margin 86%, stable vs prior quarter; non-GAAP adjusted gross margin 83%.
- Operating expenses down 4.5% YoY to $21.2 million, reflecting cost optimization.
- Cash balance $174.7 million; expect $160M+ at year-end, supporting 8-15% core revenue growth.
- SPL program revenue guidance reaffirmed at $5 million, including CASGEVY royalties.

**【Q&A Key Takeaways】**
- Regulatory environment: FDA leadership changes seen as positive for cell/gene therapy innovation; no customer-reported regulatory delays.
- Cost savings: AIM delisting to save ~$0.5M/year; operational efficiency initiatives reduce cash burn.
- SeQure Dx expansion: In-vivo safety assessment demand complements ex-vivo electroporation; LMP/AAV delivery partnerships in pipeline.
- Risk management: 57% of core revenue tied to SPLs, diversifying revenue streams against macro volatility.
- Growth catalysts: New product launches in 2025, expanding into in-vivo gene therapy space with SeQure Dx.

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

- **Core Growth Momentum**: 2024 core revenue up 9% to $32.5M, with PA sales surging 36%.
- **SeQure Dx Synergy**: $2+ million 2025 contribution from gene editing safety services, leveraging 28 SPL customers and 760 instrument install base.
- **SPL Pipeline Value**: 18 clinical-stage programs with >$220M pre-commercial milestone potential, including CASGEVY royalty upside.
- **Financial Discipline**: 2025 guidance reflects cautious 8-15% core growth, balanced with $160M cash target and modest cash burn.

**【CEO Summary Section】**
- **Core Revenue Growth**: 2024 full-year core revenue reached $32.5 million, up 9% year-over-year, driven by strong PA sales (+36%) and stable SPL customer contributions.
- **SeQure Dx Acquisition**: Integrated services platform for gene editing safety assessments, enabling cross-selling to 28 active SPL customers and 760 instrument install base.
- **Instrument Base Expansion**: Installed base grew to 760 units (from 683 in 2023), with 2025 cautious optimism on capital expenditure recovery.
- **SPL Portfolio Strength**: 18 clinical-stage programs with >$220 million pre-commercial milestone potential, including CASGEVY royalty revenue.

**【CFO Financial Commentary】**
- **2024 Financials**: Total revenue $38.6 million (-6% YoY), with non-GAAP adjusted gross margin 84% and operating expenses down 13% to $72.7 million.
- **2025 Guidance**: Core revenue growth 8-15% ($32.5M - $37.5M), including $2+ million from SeQure Dx. SPL-related revenue expected at $5 million, excluding CASGEVY royalties.
- **Cash Position**: $190.3 million at year-end, targeting $160 million by year-end 2025 with disciplined cash burn.

**【Q&A Key Themes】**
- **SeQure Dx Integration**: $2+ million 2025 contribution via fee-for-service model; minimal incremental costs due to existing commercial infrastructure.
- **Market Dynamics**: Customers remain cautious on capital spending, but PA sales stability and SPL pipeline visibility support 2025 outlook.
- **SPL Growth**: 3-5 new agreements expected in 2025, aligning with 50%+ growth in nonviral biotech companies since IPO.
- **Long-Term Pipeline**: 8 potential approvals by 2028 (lymphoma, sickle cell), expanding to 12+ by 2031 with indication diversification.

Actual	-0.05	-0.03	-0.05	-0.04	-0.08	-0.06	-0.05	-0.11	-0.1	-0.11	-0.05	-0.09	-0.09	-0.11	-0.1	-0.1	-0.12	-0.12	-0.09
Forecast	-0.0675	-0.0575	-0.058	-0.066	-0.076	-0.09	-0.0775	-0.112	-0.096	-0.1009	-0.0671	-0.1257	-0.1229	-0.12	-0.1181	-0.1025	-0.1017	-0.1119	-0.0763
Surprise	+25.93%	+47.83%	+13.79%	+39.39%	-5.26%	+33.33%	+35.48%	+1.79%	-4.17%	-9.02%	+25.48%	+28.40%	+26.77%	+8.33%	+15.33%	+2.44%	-17.99%	-7.24%	-17.96%

MXCT

MXCT fundamentals

MXCT Q4 2025 Earnings

Earnings Call

You can ask Aime

MXCT

MXCT fundamentals

MXCT Q4 2025 Earnings

Earnings Call

MXCT Earnings Call Summary for Q4/2025 Mar 25, 2026

MXCT Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

MXCT Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

MXCT Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

MXCT Earnings Call Summary for Q4/20244:30 PM on Mar 11, 2025

You can ask Aime